GSK plc (NYSE:GSK) Shares Sold by Investors Research Corp

Investors Research Corp lessened its holdings in GSK plc (NYSE:GSK) by 2.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,628 shares of the pharmaceutical company’s stock after selling 432 shares during the period. Investors Research Corp’s holdings in GSK were worth $630,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of GSK. United Bank lifted its stake in GSK by 7.3% during the 3rd quarter. United Bank now owns 25,785 shares of the pharmaceutical company’s stock worth $1,054,000 after acquiring an additional 1,760 shares in the last quarter. Verdence Capital Advisors LLC lifted its stake in GSK by 25.9% during the 3rd quarter. Verdence Capital Advisors LLC now owns 6,823 shares of the pharmaceutical company’s stock worth $279,000 after acquiring an additional 1,402 shares in the last quarter. Assetmark Inc. lifted its stake in GSK by 137.2% during the 3rd quarter. Assetmark Inc. now owns 19,795 shares of the pharmaceutical company’s stock worth $809,000 after acquiring an additional 11,448 shares in the last quarter. Mesirow Financial Investment Management Inc. lifted its stake in GSK by 2.0% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after acquiring an additional 323 shares in the last quarter. Finally, Crossmark Global Holdings Inc. lifted its stake in GSK by 29.5% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 39,560 shares of the pharmaceutical company’s stock worth $1,617,000 after acquiring an additional 9,017 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on GSK. Morgan Stanley began coverage on GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and cut their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Trading Up 0.9 %

GSK opened at $40.41 on Tuesday. GSK plc has a one year low of $31.72 and a one year high of $45.93. The company has a market cap of $83.74 billion, a P/E ratio of 25.41, a PEG ratio of 1.12 and a beta of 0.58. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The business’s 50-day simple moving average is $35.61 and its 200-day simple moving average is $37.13.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, equities research analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 3.89%. GSK’s dividend payout ratio is 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.